Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G
Department of Urology, University of Innsbruck, Austria.
Eur Urol. 1999;35(5-6):523-38. doi: 10.1159/000019893.
This article summarizes the experience and results of different prostate carcinoma screening projects using total prostate-specific antigen (PSA) and percent free PSA as the initial test.
The twelve projects studied included: (1) a mass screening study using PSA as the initial test in 21,079 volunteers; (2) an investigation of the usefulness of normal and age-referenced PSA cut-offs in 1,618 men; (3) a PSA-based screening study of 2,272 asymptomatic blood donors; (4) an investigation of the evidence and significance of transition zone carcinoma in 340 men with negative digital rectal examination findings; (5) determination of percent free PSA in one retrospective and two prospective studies to determine the appropriate cutpoints for percent free PSA; (6) evaluation of the diagnostic benefit of PSA transition zone density in 308 screening volunteers; (7) a study of the impact of PSA-based screening on the percentage of incidental prostate carcinoma in 1, 543 men undergoing transurethral resection of the prostate; (8) an evaluation of the changes in total PSA and pathologic stages in radical prostatectomy over 5 years in a PSA-based mass screening program; (9) a study evaluating the probability of having prostate cancer given the patient's age, total PSA and digital rectal examination findings; (10) an evaluation of the correlation between preoperative predictors and pathologic features in radical prostatectomy specimens; (11) an investigation of the correlation of total PSA with pathologic stage and tumor volume in patients undergoing radical prostatectomy with low PSA cut-off level, and (12) a study whether age has an impact on the extension of prostate cancer.
(1) of the 21,079 volunteers, 1,618 (8%) had elevated PSA levels. Of these men, 778 (48%) underwent biopsies; 197 biopsies were positive for prostate carcinoma and 135 underwent radical prostatectomy. Ninety-five were found to be organ-confined. (2) A PSA cut-off of 2.5 ng/ml in men aged 45-49 years and of 3.5 ng/ml in men aged 50-59 years resulted in an 8% increase in the detection rate of organ-confined disease. (3) Of the 2,272 men, 284 had elevated PSA levels and prostate carcinoma was detected in 62 men. All patients underwent radical prostatectomy and histologic examination revealed organ-confined tumor in all but 8 men. (4) Ninety-eight of 340 men had biopsies positive for carcinoma; 28 of these patients (28.5%) had carcinoma that originated in the transition zone only. (5) In the retrospective study, receiver-operating characteristic curve analysis showed that by using a percent free PSA of 18% as a biopsy criterion, 37% of the negative biopsies could be eliminated although 94% of all carcinomas would still be detected. In the first prospective study, 106 of 158 men with elevated PSA levels <10.0 ng/ml were further evaluated and 37 prostate carcinomas were detected. By using a % free PSA of <22% as a biopsy criterion, 30% of the negative biopsies could be eliminated although 98% of the carcinomas would still be detected. In the second prospective study, 120 of 465 men with total PSA levels between 1.25 and 6.49 ng/ml and a % free PSA <18% were further evaluated and 27 (22.5%) were found to have prostate carcinomas. (6) Receiver-operating characteristic curve analysis for PSA transition zone density showed that by using a PSA transition zone density of >22 ng/ml/cm3 as a biopsy criterion, 24.4% of negative biopsies could be avoided without missing a single carcinoma. (7) In the prescreening era the incidence of T1a grade 1 and 2 carcinomas was 3.1% and the incidence of T1a grade 3 and T1b carcinoma was 2.3% whereas in the years after the establishment of PSA-based screening the incidence was 4.6 and 1.03% respectively. (8) The rate of organ-confined tumors increased from 28.7% in 1993 to 65.7% in 1997. (9) In this evaluation a new approach to proceed with a prostate biopsy based upon the individual risk of having prostate cancer rath
本文总结了使用总前列腺特异性抗原(PSA)和游离PSA百分比作为初始检测手段的不同前列腺癌筛查项目的经验和结果。
所研究的12个项目包括:(1)一项以PSA作为初始检测手段对21079名志愿者进行的大规模筛查研究;(2)对1618名男性中正常及按年龄划分的PSA临界值的有用性进行的调查;(3)一项对2272名无症状献血者进行的基于PSA的筛查研究;(4)对340名直肠指检结果为阴性的男性中移行区癌的证据及意义进行的调查;(5)在一项回顾性研究和两项前瞻性研究中测定游离PSA百分比,以确定游离PSA百分比的合适切点;(6)对308名筛查志愿者评估PSA移行区密度的诊断价值;(7)一项研究基于PSA的筛查对1543名接受经尿道前列腺切除术男性中偶然发现的前列腺癌百分比的影响;(8)在一项基于PSA的大规模筛查项目中,评估5年期间根治性前列腺切除术中总PSA和病理分期的变化;(9)一项研究根据患者年龄、总PSA和直肠指检结果评估患前列腺癌的概率;(10)评估根治性前列腺切除标本中术前预测指标与病理特征之间的相关性;(11)调查低PSA临界值水平下接受根治性前列腺切除术患者中总PSA与病理分期及肿瘤体积的相关性,以及(12)一项研究年龄是否对前列腺癌的扩展有影响。
(1)在21079名志愿者中,1618名(8%)PSA水平升高。在这些男性中,778名(48%)接受了活检;197例活检前列腺癌呈阳性,135例接受了根治性前列腺切除术。95例被发现为器官局限性癌。(2)45 - 49岁男性PSA临界值为2.5 ng/ml,50 - 59岁男性为3.5 ng/ml,使器官局限性疾病的检出率提高了8%。(3)在2272名男性中,284名PSA水平升高,62名检测出前列腺癌。所有患者均接受了根治性前列腺切除术,组织学检查显示除8名男性外均为器官局限性肿瘤。(4)340名男性中有98名活检前列腺癌呈阳性;其中28名患者(28.5%)的癌仅起源于移行区。(5)在回顾性研究中,受试者操作特征曲线分析表明,以游离PSA百分比18%作为活检标准,虽能检测出94%的所有癌症,但可排除37%的阴性活检。在第一项前瞻性研究中,对158名PSA水平升高<10.0 ng/ml的男性中的106名进行了进一步评估,检测出37例前列腺癌。以游离PSA百分比<22%作为活检标准,虽能检测出98%的癌症,但可排除30%的阴性活检。在第二项前瞻性研究中,对465名总PSA水平在1.25至6.49 ng/ml且游离PSA百分比<18%的男性中的120名进行了进一步评估,27名(22.5%)被发现患有前列腺癌。(6)PSA移行区密度的受试者操作特征曲线分析表明,以PSA移行区密度>22 ng/ml/cm³作为活检标准,可避免24.4%的阴性活检且不会漏诊任何癌症。(7)在筛查前时代,T1a 1级和2级癌的发生率为3.1%,T1a 3级和T1b癌的发生率为2.3%,而在基于PSA的筛查建立后的几年中,发生率分别为4.6%和1.03%。(8)器官局限性肿瘤的比例从1993年的28.7%增至1997年的